Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 17, 2010

Primary Completion Date

January 6, 2012

Study Completion Date

January 6, 2012

Conditions
Nausea and VomitingPainSleep DisordersUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

methadone hydrochloride

"Level 1: 1 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA\*\* per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h\* (maximum 6 BTA per day)"

OTHER

questionnaire administration

within 48 hours of registration

PROCEDURE

management of therapy complications

if required

Trial Locations (7)

T6G 1Z2

Cross Cancer Institute, Edmonton

V1Y 5L3

BCCA - Cancer Centre for the Southern Interior, Kelowna

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

H2W 1S6

McGill University - Dept. Oncology, Montreal

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK